UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000040444
Receipt number R000046156
Scientific Title Development of a new system for evaluating visual function in diabetic retinopathy using EvokeDx
Date of disclosure of the study information 2020/05/20
Last modified on 2021/06/02 13:46:12

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Development of a new system for evaluating visual function in diabetic retinopathy using EvokeDx

Acronym

DREX Study

Scientific Title

Development of a new system for evaluating visual function in diabetic retinopathy using EvokeDx

Scientific Title:Acronym

DREX Study

Region

Japan


Condition

Condition

diabetic retinopathy

Classification by specialty

Ophthalmology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

Development of a new system for evaluating visual function in diabetic retinopathy using EvokeDx

Basic objectives2

Others

Basic objectives -Others

To evaluate the relationship between the grade of diabetic retinopathy and visual function.

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Visual function measured by EvokeDx

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

100 years-old >

Gender

Male and Female

Key inclusion criteria

Healthy adults and Diabetic patients who have best-corrected visual acuity better than 0.7 in decimal.

Key exclusion criteria

Patients with diabetic macular edema, galucoma, and who had been treated diabetic retinopathy within 12 weeks. If the researchers found the person not suitable for the study, the person will be excluded from the study.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Yoko
Middle name
Last name Ozawa

Organization

St Luke's International Hospital

Division name

Department of Ophthalmology

Zip code

1048560

Address

9-1 Akashicho Chuoku Tokyo Japan

TEL

03-3451-5151

Email

ozaway@luke.ac.jp


Public contact

Name of contact person

1st name Yoko
Middle name Department of Ophthalmology
Last name Ozawa

Organization

St Luke's International Hospital

Division name

Department of Ophthalmology

Zip code

1048560

Address

9-1 Akashicho Chuoku Tokyo Japan

TEL

03-3451-5151

Homepage URL


Email

ozaway@luke.ac.jp


Sponsor or person

Institute

St Luke's International University

Institute

Department

Personal name



Funding Source

Organization

SENJU PHARMACEUTICAL CO., LTD.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ethics Committee of St Luke's International Hospital

Address

9-1 Akashicho Chuoku Tokyo Japan

Tel

03-3451-5151

Email

kenkyukikaku@luke.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2020 Year 05 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2020 Year 05 Month 19 Day

Date of IRB

2020 Year 07 Month 02 Day

Anticipated trial start date

2020 Year 07 Month 02 Day

Last follow-up date

2023 Year 08 Month 31 Day

Date of closure to data entry

2023 Year 12 Month 31 Day

Date trial data considered complete

2023 Year 12 Month 31 Day

Date analysis concluded

2023 Year 12 Month 31 Day


Other

Other related information

NONE


Management information

Registered date

2020 Year 05 Month 19 Day

Last modified on

2021 Year 06 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046156


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name